search
Back to results

The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis

Primary Purpose

Sepsis, Hyperglycemia, Critical Illness

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SGC directed glycemic control
Sponsored by
Southeast University, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Admitted to the ICU
  2. At least one BG measurement 9.0mmol/L or higher
  3. Expected to stay in ICU ≥3 days;
  4. critically ill patients with sepsis
  5. SOFA score≤2

Exclusion Criteria:

  1. Aged < 18 years;
  2. Admitted because of diabetic ketoacidosis or nonketotic hyperosmolar state
  3. Pregnant
  4. In a state in which death was perceived as imminent
  5. Without written informed consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    conventional empirical glycemic control

    Arm Description

    the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.

    Outcomes

    Primary Outcome Measures

    glucose variability
    mean blood glucose, standard deviation (SD) for the mean glucose,minimum and maximum glucose levels

    Secondary Outcome Measures

    HLADr

    Full Information

    First Posted
    November 17, 2016
    Last Updated
    November 29, 2016
    Sponsor
    Southeast University, China
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02980588
    Brief Title
    The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis
    Official Title
    Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Sepsis in ICU
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    December 2016 (undefined)
    Primary Completion Date
    May 2017 (Anticipated)
    Study Completion Date
    September 2017 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Southeast University, China

    4. Oversight

    5. Study Description

    Brief Summary
    Poorly glycemic control in critically ill patients can increase their mortality, while safe and efficient glucose control is laborious and time-consuming. The Space Glucose Control which is installed with eMPC(enhanced Model Predictive Control) can get the blood glucose target range safely and effectively through regulating insulin dose rate, and decrease the glucose variability. This study is a random controlled trial involving the patients with sepsis in intensive care unit in order to evaluate the difference of safety and efficacy of blood glucose control between SGC directed and conventional treatment. At last, the trial results can determine whether the Space Glucose Control can control blood glucose safely and effectively in the patients with sepsis in intensive care units.
    Detailed Description
    Design: The study was conducted as a single-centre, open randomized controlled, parallel trial. Study population: Adult general ICU patients with sepsis and assumed to require at least 3 days of intensive care were recruited. Patients fulfilling the inclusion criterion of glucose≥9.0 mmol/L were randomly assigned using serially numbered to either the intervention group (BG control by SGC) or the control group (conventional empiric BG management). The both group aim to establish the BG levels 5.8-8.9mmol/L. Study protocol: BG measurements were performed using glucometer to test the fingertip capillary blood sample for the BG levels. As for patients with shock or required vasopressor, arterial BG was sampled to measure through the glucometer. Insulin was infused intravenously applying the standard perfusor of the ICU. Average glucose, glucose variability, SOFA score, APACHE II score, and HLA-DR were recorded. All trial-related activities were carried out until the end of the patient's ICU stay, or for a period of 72 hours. Meanwhile, enteral and parenteral nutrition was administrated to patients according to their condition. Statistical analysis was performed on an intention-to-treat basis. The percentage of values in the target range (5.8-8.9mmol/L) was defined as primary end point for the assessment of glucose control. Data are reported as mean±SD values if not otherwise indicated. Data analysis was performed using SPSS19.0.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Sepsis, Hyperglycemia, Critical Illness

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    conventional empirical glycemic control
    Arm Type
    Other
    Arm Description
    the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
    Intervention Type
    Device
    Intervention Name(s)
    SGC directed glycemic control
    Intervention Description
    the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
    Primary Outcome Measure Information:
    Title
    glucose variability
    Description
    mean blood glucose, standard deviation (SD) for the mean glucose,minimum and maximum glucose levels
    Time Frame
    up to 3days
    Secondary Outcome Measure Information:
    Title
    HLADr
    Time Frame
    up to 3days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Admitted to the ICU At least one BG measurement 9.0mmol/L or higher Expected to stay in ICU ≥3 days; critically ill patients with sepsis SOFA score≤2 Exclusion Criteria: Aged < 18 years; Admitted because of diabetic ketoacidosis or nonketotic hyperosmolar state Pregnant In a state in which death was perceived as imminent Without written informed consent
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Min Mo, Doctor
    Phone
    13914719904
    Email
    momin_2002@163.com

    12. IPD Sharing Statement

    Learn more about this trial

    The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis

    We'll reach out to this number within 24 hrs